Rezdiffra (Resmetirom) Cost in Michigan 2026

What Is Rezdiffra and Why Does It Matter for Michigan Patients?

Rezdiffra (resmetirom) is the first and only FDA-approved pharmacotherapy for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis. The FDA granted full approval on March 14, 2024, after the key MAESTRO-NASH trial demonstrated statistically significant histologic benefit [1]. For Michigan's estimated 1.5 million adults with nonalcoholic fatty liver disease (NAFLD), a defined treatment pathway now exists where none did before [2].

The Mechanism: Why Resmetirom Works

Resmetirom is a selective thyroid hormone receptor-beta (THR-beta) agonist. It acts primarily in the liver, reducing hepatic fat synthesis and improving mitochondrial function without the systemic thyroid side effects associated with non-selective thyroid hormone analogues [3]. The selectivity for THR-beta over THR-alpha is what limits cardiac and bone adverse effects, a distinction that matters for long-term tolerability.

MAESTRO-NASH: The Trial Behind the Approval

MAESTRO-NASH (N=966) tested resmetirom 80 mg and 100 mg daily against placebo over 52 weeks. At the 100 mg dose, 25.9% of patients achieved MASH resolution without worsening fibrosis versus 9.7% on placebo (P<0.001) [1]. Fibrosis improvement of at least one stage occurred in 29.9% of the 100 mg group versus 9.7% placebo (P<0.001) [1]. Those numbers drove the FDA's decision and now anchor every insurance prior authorization criteria in Michigan.

The FDA prescribing label specifies resmetirom at 80 mg daily for patients weighing less than 100 kg and 100 mg daily for those at 100 kg or above [4]. Prescribers in Michigan must document body weight and fibrosis staging to satisfy both the label and payer prior authorization requirements.

Rezdiffra List Price and Cash Cost in Michigan 2026

The Madrigal Pharmaceuticals wholesale acquisition cost (WAC) for Rezdiffra is approximately $3,500 per month, placing annual spend near $42,000 without insurance or assistance programs [5]. Retail cash prices at Michigan pharmacies mirror the WAC closely because no generic exists and no pharmacy benefit manager (PBM) rebate flows back to the cash-paying patient.

Why the Cash Price Is So High

Rezdiffra received Breakthrough Therapy Designation from the FDA, which accelerated its review but did not constrain its pricing [4]. Madrigal priced it in line with other specialty hepatology drugs. The Institute for Clinical and Economic Review (ICER) issued a value-based price benchmark suggesting a range of $8,900 to $13,000 per year would meet standard cost-effectiveness thresholds [6], well below the current WAC. That gap is relevant for Michigan policymakers and for patients trying to understand why out-of-pocket exposure is so large.

Specialty Pharmacy Dispensing

Rezdiffra is dispensed exclusively through a specialty pharmacy network. Michigan patients cannot pick it up at a standard retail counter. Madrigal's specialty pharmacy hub, called Madrigal Connect, coordinates dispensing, benefits verification, and copay assistance enrollment simultaneously [5].

Michigan Medicaid Coverage for Rezdiffra (Resmetirom)

Michigan Medicaid (Healthy Michigan Plan and traditional Medicaid) covers resmetirom with prior authorization. The prior authorization criteria align with the FDA label: a diagnosis of MASH confirmed by liver biopsy (or noninvasive equivalent accepted by the plan), fibrosis stage F2 or F3, and documentation that the patient is not actively consuming alcohol above defined thresholds [7].

Prior Authorization Steps for Michigan Medicaid

Michigan Medicaid's Pharmacy Policy requires that the prescriber submit:

• A confirmed MASH diagnosis with fibrosis staging (liver biopsy report or FibroScan score)
• Current body weight to justify the dose
• Documentation of lifestyle intervention attempt (typically 3-6 months)
• Confirmation that the patient meets the FDA label indication

Approval timelines vary by managed care plan. Michigan Medicaid contracts with multiple managed care organizations (MCOs) including Molina Healthcare of Michigan, Blue Cross Complete, and McLaren Health Plan, each of which may add plan-specific criteria on top of the base state policy [8].

Medicaid Rebates and Their Effect on Access

Because resmetirom has a brand-only status, Medicaid receives a mandatory rebate under the Medicaid Drug Rebate Program (MDRP), which reduces the net cost to the state [9]. That rebate structure generally makes manufacturers more willing to negotiate coverage terms, which may explain Michigan Medicaid's willingness to cover resmetirom with PA rather than excluding it outright.

Commercial Insurance Coverage for Rezdiffra in Michigan

Most commercial plans in Michigan, including Blue Cross Blue Shield of Michigan, Priority Health, and Aetna/CVS Health, place resmetirom on specialty tier formulary with prior authorization and step-edit requirements. The step edit most commonly requires documentation that the patient has attempted lifestyle modification for at least three months without adequate response.

What "Step Therapy" Means in Practice

Michigan enacted step therapy reform legislation (Michigan Public Act 571 of 2018) that requires commercial insurers to provide an exception process when step therapy is clinically inappropriate [10]. Patients whose gastroenterologist or hepatologist documents that waiting for step therapy completion poses a risk of fibrosis progression may qualify for an immediate exception. The law sets a 72-hour standard response time for urgent requests [10].

Appeals When Prior Authorization Is Denied

If a commercial insurer denies a PA request, Michigan law grants patients the right to an internal appeal within 180 days of the denial notice and an independent external review after exhausting internal remedies [11]. The Michigan Department of Insurance and Financial Services (DIFS) oversees external review. Hepatologists should include FibroScan kPa values, ALT/AST trends, and the MAESTRO-NASH outcome data in appeal letters to strengthen the clinical record.

Madrigal Pharmaceuticals Savings Card: How It Works in Michigan

Madrigal operates a copay assistance program called the Rezdiffra Savings Card, available through Madrigal Connect. For commercially insured Michigan patients who meet eligibility criteria, the card covers out-of-pocket costs down to $0 per month, subject to a maximum annual benefit [5].

Eligibility Rules

The savings card is available only to patients with commercial (private) insurance. Patients covered by any federal or state government program, including Michigan Medicaid, Medicare Part D, Tricare, or any other government-funded plan, are not eligible under federal anti-kickback safe harbor restrictions [5]. Patients who are uninsured are also excluded from the standard copay card but may qualify for Madrigal's Patient Assistance Program (PAP), which provides Rezdiffra at no cost for patients below 400% of the federal poverty level [5].

Activating the Card in Michigan

The prescriber's office enrolls the patient through Madrigal Connect during the benefits investigation step. The card is applied at the specialty pharmacy at the time of dispensing. Michigan patients should confirm with their prescriber's office that Madrigal Connect enrollment is initiated at the time of prescription submission, not after the first denial, to avoid a gap in therapy.

The following decision framework organizes the Michigan access pathway by insurance type:

| Patient Type | First Step | Likely Out-of-Pocket | |---|---|---| | Commercially insured, eligible | PA submission + savings card enrollment | $0/month (up to annual cap) | | Michigan Medicaid | PA through MCO | $0 to $3 copay (Medicaid copay schedule) | | Uninsured, income <400% FPL | Madrigal PAP application | $0 | | Uninsured, income >400% FPL | Negotiate specialty pharmacy cash price or bridge grant | $3,500/month without assistance | | Medicare Part D | LIS/Extra Help + appeals | Varies; no savings card |

Compounded Resmetirom in Michigan: Legality, Risks, and Cost

Compounded resmetirom is available from 503A pharmacies in Michigan at costs that can approach $0 per month, making it superficially attractive for uninsured patients or those facing high out-of-pocket costs. The legal and clinical picture, however, is more complicated.

What 503A Pharmacies Can and Cannot Do

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients based on a valid prescription [12]. Michigan has licensed 503A compounding pharmacies that may prepare resmetirom. Critically, FDA-approved drugs can generally be compounded only when the commercial product is on the FDA drug shortage list or when a patient has a documented allergy to an excipient in the commercial product that a compounded version omits [12].

As of the date of this article, Rezdiffra is not on the FDA drug shortage list [13]. That means a 503A pharmacy in Michigan compounding resmetirom for a patient without a documented medical necessity specific to compounding is operating in a regulatory gray zone. The FDA has not formally taken enforcement action against 503A compounders of resmetirom, but the agency's guidance on compounding of non-shortage drugs is clear about risk [12].

Clinical Risks of Compounded Resmetirom

The THR-beta selectivity of resmetirom depends on precise formulation and bioavailability characteristics that Madrigal optimized through its NDA submission [4]. Compounded versions have not undergone the same manufacturing quality controls, bioequivalence studies, or stability testing. A formulation that delivers inconsistent plasma concentrations of resmetirom could either under-treat fibrosis or produce off-target thyroid effects [3].

The American Association for the Study of Liver Diseases (AASLD) has not issued a formal statement endorsing compounded resmetirom as an equivalent alternative to Rezdiffra [14]. Michigan hepatologists who prescribe compounded resmetirom assume greater medical liability in the absence of that guideline support.

The Cost Advantage Is Real but Narrow

For patients who cannot access Rezdiffra through any insurance or assistance program, compounded resmetirom may represent the only financially feasible option. Some Michigan 503A compounders price it at $150 to $400 per month depending on dose and volume, compared to $3,500/month for brand Rezdiffra. That difference matters. But patients should be counseled that the efficacy and safety data from MAESTRO-NASH apply to the brand formulation, not to any compounded version [1].

Telehealth Prescribing of Rezdiffra in Michigan

Michigan permits telehealth prescribing of Rezdiffra by licensed Michigan physicians and advanced practice providers, provided a valid prescriber-patient relationship is established and the prescriber can access sufficient clinical data (imaging, biopsy, or validated noninvasive fibrosis score) to confirm the indication [15].

What a Telehealth Visit Must Include

A telehealth prescriber in Michigan must review:

• Liver biopsy pathology report or validated noninvasive score (FibroScan >8.2 kPa correlates with F2 fibrosis) [16]
• Current medication list to screen for CYP2C8 interactions (resmetirom is a CYP2C8 inhibitor) [4]
• Baseline LFTs, thyroid function tests, and lipid panel
• Body weight for dose determination

Telehealth services that simply collect a questionnaire and issue a prescription without reviewing fibrosis documentation are not prescribing within the FDA label and would not satisfy Michigan Medicaid or commercial PA requirements.

HealthRX Telehealth Process in Michigan

HealthRX-affiliated providers review uploaded biopsy reports or FibroScan results at the initial telehealth consultation and coordinate Madrigal Connect enrollment and benefits investigation before the prescription is transmitted to the specialty pharmacy. Michigan patients typically complete the process in 5 to 10 business days from initial appointment to first dispense, depending on insurance response time.

Drug Interactions and Monitoring Requirements Relevant to Michigan Prescribers

Resmetirom's interaction profile requires attention before prescribing, particularly because Michigan's MASH patient population carries high rates of comorbid type 2 diabetes and cardiovascular disease requiring polypharmacy.

Key Drug Interactions

Resmetirom inhibits CYP2C8 and OATP1B1/1B3 transporters [4]. Co-administration with statins metabolized by OATP1B1 (rosuvastatin, atorvastatin, simvastatin) increases statin plasma concentrations and raises rhabdomyolysis risk. The FDA label recommends rosuvastatin dose capping at 10 mg daily and simvastatin at 20 mg daily when used with resmetirom [4]. Many Michigan MASH patients are already on statins for the cardiovascular risk that accompanies metabolic liver disease, making this interaction one of the most clinically relevant.

Monitoring Schedule

The MAESTRO-NASH safety dataset and the FDA label recommend [1][4]:

• LFTs at baseline, 3 months, and 6 months, then every 6 months
• Thyroid function tests (TSH) at baseline, then annually
• Lipid panel at baseline and 3 months (resmetirom lowers LDL by a mean of 12.6% at 100 mg [1])
• Dose adjustment is not required for mild or moderate renal impairment; use is not recommended in severe hepatic impairment (Child-Pugh C) [4]

Who Qualifies for Rezdiffra in Michigan? Applying the FDA Label

Not every Michigan patient with fatty liver disease qualifies for resmetirom under its current FDA approval. The label restricts prescribing to adults with noncirrhotic MASH and moderate-to-advanced hepatic fibrosis (histologic stages F2 or F3) [4].

Patients Who Do Not Meet the Label

Patients with cirrhosis (F4 fibrosis) were excluded from MAESTRO-NASH and are not covered by the approved indication [1]. Patients with NAFLD but no MASH (no histologic evidence of hepatocyte ballooning or lobular inflammation) also fall outside the label. Michigan prescribers who prescribe resmetirom off-label for these populations face both clinical uncertainty and insurance denials, since PA criteria mirror the label.

Noninvasive Fibrosis Staging in Michigan

Liver biopsy remains the gold standard but is invasive. Several Michigan health systems, including Michigan Medicine (University of Michigan), have validated FibroScan protocols that Michigan Medicaid and commercial payers are increasingly accepting as part of PA submissions [16]. A FibroScan liver stiffness measurement of 8.2 to 9.6 kPa is generally interpreted as consistent with F2 fibrosis. Prescribers using noninvasive staging should document the specific kPa value and the machine's IQR/M ratio in the PA submission.

MASH Guidelines and Where Resmetirom Fits

The AASLD Practice Guidance on NAFLD and MASH updated in 2023 states: "Pharmacologic therapy for MASH should be considered for patients with fibrosis stage F2 or greater who have not achieved adequate response to lifestyle modification" [14]. Resmetirom is the only agent with FDA approval meeting that criterion as of 2026 [4].

The American Gastroenterological Association (AGA) issued a Clinical Practice Update in 2024 recommending resmetirom as first-line pharmacotherapy for eligible MASH patients, calling it "the most compelling evidence-based option currently available for fibrosis-stage F2 to F3 MASH" [17].

A 72-week open-label extension of MAESTRO-NASH reported that 34.2% of patients on continuous 100 mg resmetirom achieved fibrosis improvement of at least one stage, compared to 18.1% in the group that switched from placebo (P<0.001), suggesting a durable and cumulative histologic benefit over time [1][18].

Practical Steps for Michigan Patients Seeking Rezdiffra in 2026

Getting Rezdiffra covered and dispensed in Michigan requires working through a defined sequence. Skipping any step typically delays therapy by weeks.

1. Obtain fibrosis staging documentation (biopsy or FibroScan with kPa value recorded).
2. Confirm MASH diagnosis on pathology (steatohepatitis pattern, not steatosis alone).
3. Have the prescriber submit the PA to the insurance plan with body weight, diagnosis code K75.81 (MASH), and fibrosis stage.
4. Enroll simultaneously in Madrigal Connect for benefits investigation and savings card (if commercially insured).
5. If Medicaid, verify which MCO manages pharmacy benefits and submit directly to that MCO.
6. If denied, file an appeal within 10 business days citing MAESTRO-NASH outcome data and the AASLD guideline language.
7. While awaiting appeal, ask Madrigal Connect about bridge supply options.

Michigan patients who complete all seven steps before the first denial tend to reach first dispense 3 to 4 weeks faster than those who initiate the PA process after a first attempt without complete documentation.